Cargando…

Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease

Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kazankov, Konstantin, Rosso, Chiara, Younes, Ramy, Armandi, Angelo, Hagström, Hannes, Møller, Holger Jon, Stål, Per, Bugianesi, Elisabetta, Grønbæk, Henning
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775526/
https://www.ncbi.nlm.nih.gov/pubmed/33392234
http://dx.doi.org/10.3389/fmed.2020.616212
_version_ 1783630487072276480
author Kazankov, Konstantin
Rosso, Chiara
Younes, Ramy
Armandi, Angelo
Hagström, Hannes
Møller, Holger Jon
Stål, Per
Bugianesi, Elisabetta
Grønbæk, Henning
author_facet Kazankov, Konstantin
Rosso, Chiara
Younes, Ramy
Armandi, Angelo
Hagström, Hannes
Møller, Holger Jon
Stål, Per
Bugianesi, Elisabetta
Grønbæk, Henning
author_sort Kazankov, Konstantin
collection PubMed
description Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibrosis in MAFLD. In the present study we tested whether the combination of macrophage markers and TE improves fibrosis prediction. Methods: We measured macrophage markers soluble (s)CD163 and mannose receptor (sMR) in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with biopsy-proven MAFLD and available TE. Results: In the Italian cohort, TE and sCD163 showed similar moderate associations with liver fibrosis (rho = 0.56, p < 0.001 and rho = 0.42, p < 0.001, respectively). TE had an area under the Receiver Operating Characteristics curve (AUROC, with 95% CI) for fibrosis; F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.81 (0.73–0.89), F4 = 0.95 (0.90–1.0). sCD163 also predicted fibrosis well [F ≥ 2 = 0.71 (0.63–0.80), F ≥ 3 = 0.82 (0.74–0.90), F4 = 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs significantly [F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.85 (0.78–0.92), F4 = 0.97 (0.93–1.0)]. In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73, p < 0.001) than sCD163 (rho = 0.43, p < 0.001) and sMR (rho = 0.46, p < 0.001). TE predicted fibrosis well [F ≥ 2 = 0.88 (0.80–0.97), F ≥ 3 = 0.90 (0.83–0.97), F4 = 0.87 (0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better prediction [F ≥ 2 = 0.68 (0.56–0.81), F ≥ 3 = 0.82 (0.71–0.92), F4 = 0.79 (0.66–0.93)], but the addition of sMR did not further improve the prediction of fibrosis by TE. Conclusion: In these cohorts of MAFLD patients, TE was superior to macrophage markers for fibrosis prediction and in contrast to our hypothesis the addition of these markers to TE did not improve its predictive capability.
format Online
Article
Text
id pubmed-7775526
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77755262021-01-02 Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease Kazankov, Konstantin Rosso, Chiara Younes, Ramy Armandi, Angelo Hagström, Hannes Møller, Holger Jon Stål, Per Bugianesi, Elisabetta Grønbæk, Henning Front Med (Lausanne) Medicine Background and Aims: Non-invasive fibrosis staging is essential in metabolic associated fatty liver disease (MAFLD). Transient elastography (TE) is a well-established method for liver fibrosis assessment. We have previously shown that the macrophage marker sCD163 is an independent predictor for fibrosis in MAFLD. In the present study we tested whether the combination of macrophage markers and TE improves fibrosis prediction. Methods: We measured macrophage markers soluble (s)CD163 and mannose receptor (sMR) in two independent cohorts from Italy (n = 141) and Sweden (n = 70) with biopsy-proven MAFLD and available TE. Results: In the Italian cohort, TE and sCD163 showed similar moderate associations with liver fibrosis (rho = 0.56, p < 0.001 and rho = 0.42, p < 0.001, respectively). TE had an area under the Receiver Operating Characteristics curve (AUROC, with 95% CI) for fibrosis; F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.81 (0.73–0.89), F4 = 0.95 (0.90–1.0). sCD163 also predicted fibrosis well [F ≥ 2 = 0.71 (0.63–0.80), F ≥ 3 = 0.82 (0.74–0.90), F4 = 0.89 (0.76–1.0)]. However, combining sCD163 and TE did not improve the AUROCs significantly [F ≥ 2 = 0.79 (0.72–0.86), F ≥ 3 = 0.85 (0.78–0.92), F4 = 0.97 (0.93–1.0)]. In the Swedish cohort, TE showed a closer association with fibrosis (rho = 0.73, p < 0.001) than sCD163 (rho = 0.43, p < 0.001) and sMR (rho = 0.46, p < 0.001). TE predicted fibrosis well [F ≥ 2 = 0.88 (0.80–0.97), F ≥ 3 = 0.90 (0.83–0.97), F4 = 0.87 (0.78–0.96)], whereas sCD163 did not (best AUROC 0.75). sMR showed a better prediction [F ≥ 2 = 0.68 (0.56–0.81), F ≥ 3 = 0.82 (0.71–0.92), F4 = 0.79 (0.66–0.93)], but the addition of sMR did not further improve the prediction of fibrosis by TE. Conclusion: In these cohorts of MAFLD patients, TE was superior to macrophage markers for fibrosis prediction and in contrast to our hypothesis the addition of these markers to TE did not improve its predictive capability. Frontiers Media S.A. 2020-12-18 /pmc/articles/PMC7775526/ /pubmed/33392234 http://dx.doi.org/10.3389/fmed.2020.616212 Text en Copyright © 2020 Kazankov, Rosso, Younes, Armandi, Hagström, Møller, Stål, Bugianesi and Grønbæk. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Kazankov, Konstantin
Rosso, Chiara
Younes, Ramy
Armandi, Angelo
Hagström, Hannes
Møller, Holger Jon
Stål, Per
Bugianesi, Elisabetta
Grønbæk, Henning
Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title_full Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title_fullStr Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title_full_unstemmed Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title_short Macrophage Markers Do Not Add to the Prediction of Liver Fibrosis by Transient Elastography in Patients With Metabolic Associated Fatty Liver Disease
title_sort macrophage markers do not add to the prediction of liver fibrosis by transient elastography in patients with metabolic associated fatty liver disease
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7775526/
https://www.ncbi.nlm.nih.gov/pubmed/33392234
http://dx.doi.org/10.3389/fmed.2020.616212
work_keys_str_mv AT kazankovkonstantin macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT rossochiara macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT younesramy macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT armandiangelo macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT hagstromhannes macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT møllerholgerjon macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT stalper macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT bugianesielisabetta macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease
AT grønbækhenning macrophagemarkersdonotaddtothepredictionofliverfibrosisbytransientelastographyinpatientswithmetabolicassociatedfattyliverdisease